Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 21:00:00 14/05/2025 BST			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 26.16M 24.74M 22.44M 42.14M 2.86B 42.38M 296M 114M 1.46B 112M 109M 4.68B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -41.27M -39.02M -35.39M -66.47M -4.5B -66.85M -467M -180M -2.3B -176M -172M -7.39B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
15/05/25	Allakos Inc. Announces Executive Changes	CI
14/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
14/05/25	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
08/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
07/05/25	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/04/25	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
02/04/25	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
01/04/25	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
27/01/25	Top Midday Decliners	MT

17/01/24	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
17/01/24	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
17/01/24	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
16/01/24	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
16/01/24	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Share Price

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news: Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

22/07/22	Lonza-Aktien sinken nach Halbjahreszahlen
05/12/19	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
05/12/19	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/05/25	Steven James	Issuer sale	Director	332,932	0.3726%
15/05/25	Neil Graham	Issuer sale	Director	195,786	0.2191%
15/05/25	BVF Partners LP	Issuer sale	Company	16,312,872	18.2586%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-86.84%	29.74M
LONZA GROUP AG	+2.64%	+7.07%	+11.87%	+38.40%	47.97B
IQVIA HOLDINGS INC.	+0.22%	+1.71%	+50.91%	+34.00%	44.5B
REVOLUTION MEDICINES, INC.	-1.58%	+5.65%	+359.34%	+598.06%	43.93B
BEONE MEDICINES AG	+1.70%	+4.61%	+12.56%	+90.97%	41.03B
CELLTRION, INC.	+0.51%	-0.61%	+5.18%	+46.87%	29.85B
MEDPACE HOLDINGS, INC.	-0.48%	+0.59%	+23.98%	+148.36%	17.27B
TEMPUS AI, INC.	+0.08%	+9.30%	+8.41%	-	15.34B
EUROFINS SCIENTIFIC SE	+1.76%	+2.98%	+29.13%	+45.78%	15.3B
ASCENDIS PHARMA A/S	+1.97%	-2.82%	-	-	14.82B
Average	+0.60%	+2.22%	+55.71%	+114.45%	27.01B
Weighted average by Cap.	+0.67%	+2.97%	+79.46%	+158.49%

	2023	2024
Net sales	-	-
Net income	-186M -163M -154M -140M -263M -17.83B -265M -1.85B -714M -9.1B -697M -682M -29.23B	-116M -102M -96.32M -87.37M -164M -11.12B -165M -1.15B -445M -5.67B -435M -425M -18.23B
Net Debt	-129M -114M -108M -97.56M -183M -12.41B -184M -1.29B -497M -6.33B -486M -475M -20.36B	-76.66M -67.42M -63.76M -57.83M -109M -7.36B -109M -763M -295M -3.76B -288M -282M -12.07B

3 years	0.22	3.4
5 years	0.22	112.87
10 years	0.22	157.98